Literature DB >> 8922589

Differential regulation of c-Jun and JunD by ubiquitin-dependent protein degradation.

A M Musti1, M Treier, F A Peverali, D Bohmann.   

Abstract

c-Jun and JunD are two closely related members of the Jun family of transcription factors which markedly differ in their biological functions. Whereas c-Jun behaves as a positive regulator of cell growth and may cause cell transformation when overexpressed, JunD antagonizes both of these effects. To better understand how the activities of c-Jun and JunD are controlled, we investigated how their stabilities within the cell are determined. We show that, in contrast to c-Jun which is degraded following multi ubiquitination, JunD is not efficiently ubiquitinated and exhibits a correspondingly longer half-life. Mutational analysis reveals that the determinant for the difference in ubiquitination resides in the NH2-terminal regions of the proteins which in c-Jun contains the delta-domain.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8922589     DOI: 10.1515/bchm3.1996.377.10.619

Source DB:  PubMed          Journal:  Biol Chem        ISSN: 1431-6730            Impact factor:   3.915


  11 in total

1.  Early mitotic degradation of the homeoprotein HOXC10 is potentially linked to cell cycle progression.

Authors:  Davide Gabellini; Ivan N Colaluca; Hartmut C Vodermaier; Giuseppe Biamonti; Mauro Giacca; Arturo Falaschi; Silvano Riva; Fiorenzo A Peverali
Journal:  EMBO J       Date:  2003-07-15       Impact factor: 11.598

Review 2.  Emerging roles of ATF2 and the dynamic AP1 network in cancer.

Authors:  Pablo Lopez-Bergami; Eric Lau; Ze'ev Ronai
Journal:  Nat Rev Cancer       Date:  2010-01       Impact factor: 60.716

3.  Regulation of the G1 phase of the cell cycle by periodic stabilization and degradation of the p25rum1 CDK inhibitor.

Authors:  J Benito; C Martín-Castellanos; S Moreno
Journal:  EMBO J       Date:  1998-01-15       Impact factor: 11.598

4.  Proteasomal degradation of retinoid X receptor alpha reprograms transcriptional activity of PPARgamma in obese mice and humans.

Authors:  Bruno Lefebvre; Yacir Benomar; Aurore Guédin; Audrey Langlois; Nathalie Hennuyer; Julie Dumont; Emmanuel Bouchaert; Catherine Dacquet; Luc Pénicaud; Louis Casteilla; Francois Pattou; Alain Ktorza; Bart Staels; Philippe Lefebvre
Journal:  J Clin Invest       Date:  2010-04-01       Impact factor: 14.808

5.  Cell cycle-dependent variations in c-Jun and JunB phosphorylation: a role in the control of cyclin D1 expression.

Authors:  L Bakiri; D Lallemand; E Bossy-Wetzel; M Yaniv
Journal:  EMBO J       Date:  2000-05-02       Impact factor: 11.598

6.  COOH-terminal Src kinase-mediated c-Jun phosphorylation promotes c-Jun degradation and inhibits cell transformation.

Authors:  Feng Zhu; Bu Young Choi; Wei-Ya Ma; Zhongliang Zhao; Yiguo Zhang; Yong Yeon Cho; Hong Seok Choi; Akira Imamoto; Ann M Bode; Zigang Dong
Journal:  Cancer Res       Date:  2006-06-01       Impact factor: 12.701

7.  Methylation-controlled J protein promotes c-Jun degradation to prevent ABCB1 transporter expression.

Authors:  Ketki M Hatle; Wendy Neveu; Oliver Dienz; Stacia Rymarchyk; Ramiro Barrantes; Sarah Hale; Nicholas Farley; Karen M Lounsbury; Jeffrey P Bond; Douglas Taatjes; Mercedes Rincón
Journal:  Mol Cell Biol       Date:  2007-02-05       Impact factor: 4.272

Review 8.  Multiple facets of junD gene expression are atypical among AP-1 family members.

Authors:  J M Hernandez; D H Floyd; K N Weilbaecher; P L Green; K Boris-Lawrie
Journal:  Oncogene       Date:  2008-04-21       Impact factor: 9.867

9.  JunD/AP-1-mediated gene expression promotes lymphocyte growth dependent on interleukin-7 signal transduction.

Authors:  Shannon M Ruppert; Mounir Chehtane; Ge Zhang; Haiyan Hu; Xiaoman Li; Annette R Khaled
Journal:  PLoS One       Date:  2012-02-23       Impact factor: 3.240

10.  Chronic oxidative stress promotes H2AX protein degradation and enhances chemosensitivity in breast cancer patients.

Authors:  Tina Gruosso; Virginie Mieulet; Melissa Cardon; Brigitte Bourachot; Yann Kieffer; Flavien Devun; Thierry Dubois; Marie Dutreix; Anne Vincent-Salomon; Kyle Malcolm Miller; Fatima Mechta-Grigoriou
Journal:  EMBO Mol Med       Date:  2016-05-02       Impact factor: 12.137

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.